EUVIMEDEUVIMED entdecken
Crossref

Outcomes of SWI / SNF complex‐deficient sinonasal carcinomas in a Southeast Asian cohort

Xinni Xu iD, Bingcheng Wu, Kwok Seng Loh, Wei Sian Lim, Charmaine Si Min Tan, Terese Huiying Low, Yew Kwang Ong, Jeng Swan Tan, Donovan Kum Chuen Eu

Head & Neck · 2025

DOI: 10.1002/hed.27864 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Head & Neck, 2025. Verfasst von Xinni Xu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology - Head & Neck Surgery, National University Hospital, Singapore, Singapore. Hauptthemen laut MEDLINE: SMARCB1 Protein, Carcinoma, DNA Helicases, Nuclear Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

SWI/SNF complex‐deficient sinonasal carcinomas are rare, genetically distinct, and aggressive entities.

Methods

SMARCB1 and SMARCA4 immunohistochemistry was retrospectively performed on a cohort of undifferentiated, poorly differentiated, and poorly defined sinonasal carcinomas. Survival outcomes were compared between SMARCB1/SMARCA4 (SWI/SNF complex)‐deficient and ‐retained groups.

Results

Eight SWI/SNF complex‐deficient (six SMARCB1‐deficient, two SMARCA4‐deficient) cases were identified among 47 patients over 12 years. Triple‐modality treatment was more frequently utilized in SWI/SNF complex‐deficient carcinomas than in SWI/SNF complex‐retained carcinomas (71.4% vs. 11.8%, p = 0.001). After a median follow‐up of 21.3 (IQR 9.9–56.0) months, SWI/SNF complex‐deficient sinonasal carcinomas showed comparable recurrence rates (57.1% vs. 52.9%, p = 0.839), time‐to‐recurrence (7.3 [IQR 6.6–8.3] vs. 9.1 [IQR 3.9–17.4] months, p = 0.531), and overall survival (17.7 [IQR 11.8–67.0] vs. 21.6 [IQR 8.9–56.0] months, p = 0.835) compared to SWI/SNF complex‐retained sinonasal carcinomas.

Conclusion

Triple‐modality treatment may improve survival in SWI/SNF complex‐deficient sinonasal carcinomas.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SMARCB1 ProteinCarcinomaDNA HelicasesNuclear ProteinsHumansFemaleMiddle AgedMaleRetrospective StudiesAgedTranscription FactorsCohort StudiesAdultImmunohistochemistryAsia, SoutheasternParanasal Sinus NeoplasmsNeoplasm Recurrence, LocalMaxillary Sinus NeoplasmsSoutheast Asian People

Stichwörter der Autor:innen

SMARCA4‐deficientSMARCB1‐deficientSWI/SNF complex‐deficientsinonasal carcinomaundifferentiated carcinoma

Substanzen

SMARCB1 ProteinSMARCB1 protein, humanSMARCA4 protein, humanDNA HelicasesNuclear ProteinsTranscription Factors

Autor:innen und Institutionen

  • Department of Otolaryngology - Head & Neck Surgery, National University Hospital, Singapore, Singapore.
  • Department of Pathology, National University Hospital, Singapore, Singapore.
  • Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Department of Otolaryngology - Head & Neck Surgery, Ng Teng Fong General Hospital, Singapore, Singapore.

ORCID-Profile: Xinni Xu

Zitieren

APA

Xu, X., Wu, B., Loh, K. S., Lim, W. S., Tan, C. S. M., Low, T. H., Ong, Y. K., Tan, J. S., & Eu, D. K. C. (2025). Outcomes of SWI / SNF complex‐deficient sinonasal carcinomas in a Southeast Asian cohort. Head & Neck. https://doi.org/10.1002/hed.27864

Vancouver

Xu X, Wu B, Loh KS, Lim WS, Tan CSM, Low TH, et al. Outcomes of SWI / SNF complex‐deficient sinonasal carcinomas in a Southeast Asian cohort. Head & Neck. 2025. doi:10.1002/hed.27864

BibTeX
@article{Xu2025,
  author = {Xu, Xinni and Wu, Bingcheng and Loh, Kwok Seng and Lim, Wei Sian and Tan, Charmaine Si Min and Low, Terese Huiying and Ong, Yew Kwang and Tan, Jeng Swan and Eu, Donovan Kum Chuen},
  title = {Outcomes of SWI / SNF complex‐deficient sinonasal carcinomas in a Southeast Asian cohort},
  journal = {Head & Neck},
  year = {2025},
  doi = {10.1002/hed.27864}
}
Kostenlos starten →